TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06527209

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Coffee and agave inulin-based beverage (A)
Description: Intervention beverage:~134 mL of cold-brew coffee 18 g of agave inulin Total beverage weight: 350 g

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Coffee and agave inulin-based beverage (A)
Description: Intervention beverage:~134 mL of cold-brew coffee 18 g of agave inulin Total beverage weight: 350 g

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control beverage (B)
Description: Control beverage:~40 mL of cold brew coffee 5.4 g of agave inulin Total beverage weight: 350 g.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control beverage (B)
Description: Control beverage:~40 mL of cold brew coffee 5.4 g of agave inulin Total beverage weight: 350 g.
Study: NCT05306184

Intervention type: PROCEDURE
Intervention: Electroconvulsive therapy (ECT)
Description: ECT
Study: NCT04853992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 152020
Description: LEO 152020 is a small drug molecule which can block the histamine 4 receptor (H4R). LEO 152020 is a tablet for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 152020
Description: LEO 152020 is a small drug molecule which can block the histamine 4 receptor (H4R). LEO 152020 is a tablet for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 152020 placebo
Description: LEO 152020 placebo is a tablet for oral administration. LEO 152020 placebo contains the same excipients in the same concentration as the LEO 152020 tablet, except the medical ingredient, LEO 152020.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 152020 placebo
Description: LEO 152020 placebo is a tablet for oral administration. LEO 152020 placebo contains the same excipients in the same concentration as the LEO 152020 tablet, except the medical ingredient, LEO 152020.
Study: NCT05695677

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Capacitive-Resistive Radiofrequency therapy of the neck muscles
Description: Capacitive-Resistive Radiofrequency therapy of the neck muscles as a non-invasive technique for treating PDPH.
Study: NCT05916261

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Personalized neoantigen tumor vaccine
Description: neoantigen tumor vaccine with or without Pembrolizumab In dose escalation phase, subjects will receive neoantigen tumor vaccine only. In dose expansion phase, subjects will receive neoantigen tumor vaccine combination with Pembrolizumab
Study: NCT04503395

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ESAR treatment: Endograft + Heli-FX Endoanchor
Description: ESAR treatment: Endurant II or Endurant IIs endograft + Heli-FX Endoanchor

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FEVAR treatment : Fenestrated endograft
Description: Cook Zenith Fenestrated Graft or the Terumo Fenestrated Anaconda Graft
Study: NCT03327636

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Echopulse
Description: This is a machine to apply high intensity focused ultrasound to ablation the target zone. In this study, we would apply it to the papillary thyroid microcarcinoma.
Study: NCT05073172

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calendula Ointment
Description: Applied topically

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Petrolatum-Mineral Oil-Lanolin-Ceresin Ointment
Description: Applied topically

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Polyethylene Glycol Hydrogel
Description: Applied topically

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silicone-based Film Forming Topical Gel
Description: Applied topically

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Silver Sulfadiazine
Description: Applied topically

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical Hydrocortisone
Description: Applied topically
Study: NCT05610657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitapivat
Description: Mitapivat tablets
Study: NCT06345586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drospirenone
Description: 4 mg tablet once daily
Study: NCT04163055

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Moleculight i:X
Description: This device is used to visualize the bacteria in the wound. Patients do not need consume any contrast agent prior to imaging. The device does not come in contact with the wound.
Study: NCT05315141

Intervention type: OTHER
Intervention: No Intervention
Description: No Intervention

Intervention type: OTHER
Intervention: No Intervention
Description: No Intervention

Intervention type: OTHER
Intervention: No Intervention
Description: No Intervention

Intervention type: OTHER
Intervention: No Intervention
Description: No Intervention

Intervention type: OTHER
Intervention: No Intervention
Description: No Intervention
Study: NCT05686083

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: C6 ketone di-ester
Description: C6 ketone di-ester

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Novel ketone di-ester
Description: Novel ketone di-ester

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Novel ketone di-ester
Description: Novel ketone di-ester
Study: NCT06372808

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Plyometric Exercise
Description: The training group will perform plyometric exercises for eight weeks in addition to their regular training program.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Regular Training
Description: The control group's regular training includes basic strength training, cardiovascular training, technical and tactical training, and match-style wrestling.
Study: NCT05438251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fespixon Cream
Description: 1. Name: Fespixon Cream~2. Dosage form: Topical cream, 15 g ointment per tube~3. Active ingredients: 1.25% extracts of Plectranthus amboinicus (PA-F4, 0.25%) and Centella asiatica (S1, 1%)~4. Dose(s): Apply 1 cc per 5 cm\^2 ulcer size (approximately 2 mm in thickness)~5. Dosing schedule: Apply twice a day~6. Duration: up to 12 weeks
Study: NCT05346770

Intervention type: BEHAVIORAL
Intervention: Behavioral Intervention
Description: A behavioral intervention could include changing the time of day a drug is taken.

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic Test
Description: A patient may receive a pharmacogenomic test via cheek swab to find PGx results. This is a benign intervention with little to no risk to the patient.

Intervention type: OTHER
Intervention: Data Analysis
Description: Medication safety reviews, and retrospective or prospective data analysis may occur as a result of participation in a case study.
Study: NCT06300931

Intervention type: OTHER
Intervention: educational lecture
Description: An Educational lecture about SDF
Study: NCT06557798

Intervention type: DEVICE
Intervention: Any commercially available transcatheter aortic valve
Description: Redo TAVI will be performed using any commercially available transcatheter aortic valve according to the preferences of the local team in keeping with standard clinical care.
Study: NCT06426446

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Withings Body Comp Pro
Description: Withings Body Comp Pro from which the following features will be used: body weight, body composition (fat, muscle and bone mass, cardiovascular health (pulse wave velocity, arterial stiffness, vascular age, standing heart rate), nervous health (electrochemical skin conductance)
Study: NCT05050006

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ITIL-168
Description: ITIL-168 is a cell therapy product derived from a patient's own TILs. A tumor sample is removed from each patient to make a personalized ITIL-168 product. Once ITIL-168 has been made, the patient is treated with 5 days of lymphodepleting chemotherapy including cyclophosphamide and fludarabine, followed by a single infusion of ITIL-168, and up to 8 doses of IL-2.
Study: NCT05067621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide Pen Injector
Description: Semaglutide (Wegovy) pen is a subcutaneous injection that contains 2.4mg/0.75mL of active ingredient. The injection pen can deliver doses of 0.24mg, 0.5mg, 1.0mg, 1.7mg, and 2.4mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injection pen contains excipients.
Study: NCT04856826

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasound guidance and therapeutic communication
Description: insertion of a peripheral venous catheter with ultrasound guidance and therapeutic communication
Study: NCT06557798

Intervention type: PROCEDURE
Intervention: Surgical explantation and aortic valve replacement
Description: Surgical explantation and aortic valve replacement will be performed according to the preferences of the local team in keeping with standard clinical care. Any commercially available approved surgical aortic valve may be used. Additional surgery, such as aortic root replacement, root enlargement, CABG, mitral valve repair/replacement, etc. will be performed at the discretion of the local team.

Intervention type: OTHER
Intervention: Conservative management
Description: Conservative treatment, including optimal medical therapy +/- balloon aortic valvuloplasty
Study: NCT04571879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebulized Lidocaine
Description: Nebulized Lidocaine for Reducing Pain of Nasogastric Tube Insertion in Children

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Midazolam
Description: Intranasal Midazolam for reducing anxiety of Nasogastric Tube insertion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Midazolam
Description: Intranasal Midazolam for reducing anxiety of Nasogastric Tube insertion

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Nebulized normal saline and intranasal normal sline
Study: NCT06505044

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: aerobic exercise
Description: aerobic exercise.~* Intensity: according to heart rate (60-75% of maximum heart rate) MHR=220-age.~* Heart rate: determined by the sensor of a treadmill.~* Duration: 40-50 min per session. Each session consisted of 5-10 minutes of warming up exercise on a treadmill without increasing speed or intensity and the same for the cooling down phase. There was 30 minutes of conditioning exercise including increasing the treadmill speed till reaching (60-75%) of the maximum heart rate.~* Frequency: 3 times/week for 12 weeks in addition to their usual daily calcium intake.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: aerobic exercise
Description: aerobic exercise.~* Intensity: according to heart rate (60-75% of maximum heart rate) MHR=220-age.~* Heart rate: determined by the sensor of a treadmill.~* Duration: 40-50 min per session. Each session consisted of 5-10 minutes of warming up exercise on a treadmill without increasing speed or intensity and the same for the cooling down phase. There was 30 minutes of conditioning exercise including increasing the treadmill speed till reaching (60-75%) of the maximum heart rate.~* Frequency: 3 times/week for 12 weeks in addition to their usual daily calcium intake.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: resistance exercise
Description: resisted exercise program for 12 weeks

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: resistance exercise
Description: resisted exercise program for 12 weeks
Study: NCT06209177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARO-CFB
Description: ARO-CFB for sc injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARO-CFB
Description: ARO-CFB for sc injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: sterile normal saline (0.9% NaCl for sc injection)
Study: NCT04173559

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Activity Intervention
Description: After 1 week of baseline activity is obtained, participants will be contacted with personalized activity goals that are 10% higher than their previous weeks' activity levels. They will also receive feedback regarding sleep if they are not averaging at least 6 hours per night or if they are waking more than twice per night. Participants will also receive weekly text reminders and encouraging feedback, and will receive additional counseling in person at regularly scheduled prenatal visits until delivery.
Study: NCT05796323

Intervention type: OTHER
Intervention: No intervention.
Description: The subjects will complete a survey related to workplace violance.
Study: NCT05075486

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Collaborative quality improvement
Description: Hospitals will receive standardized center-specific ECLS data report with benchmarking to feedback on their performance. Evidence-based potential better practice list will be established as a reference for all hospitals. During the intervention period, the hospitals will receive training in collaborative quality improvement method and then develop, implement, and document evidence-based practice changes to reduce adverse outcomes of neonatal ECLS treatment. Compliance with practice changes and neonatal outcomes will be monitored. All hospitals will have access to implementation support and collaborative activities.
Study: NCT05050006

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ITIL-168
Description: ITIL-168 is a cell therapy product derived from a patient's own TILs. A tumor sample is removed from each patient to make a personalized ITIL-168 product. Once ITIL-168 has been made, the patient is treated with 5 days of lymphodepleting chemotherapy including cyclophosphamide and fludarabine, followed by a single infusion of ITIL-168, and up to 8 doses of IL-2.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ITIL-168
Description: ITIL-168 is a cell therapy product derived from a patient's own TILs. A tumor sample is removed from each patient to make a personalized ITIL-168 product. Once ITIL-168 has been made, the patient is treated with 5 days of lymphodepleting chemotherapy including cyclophosphamide and fludarabine, followed by a single infusion of ITIL-168, and up to 8 doses of IL-2.
Study: NCT04702984

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LID021201 contact lenses
Description: Investigational silicone hydrogel sphere contact lenses for frequent replacement daily wear

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OPTI-FREE multipurpose solution
Description: Solution for cleaning, disinfecting, and reconditioning silicone hydrogel contact lenses
Study: NCT05932992

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mother education on how to perform MUAC assessment
Description: Mothers will be trained to perform MUAC weekly on their children
Study: NCT05533762

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: arch insole and sham insole
Description: children wear insoles on feet

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: arch insole and sham insole
Description: children wear insoles on feet
Study: NCT05496335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-151586
Description: Intramuscular Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOTOX
Description: Intramuscular Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOTOX
Description: Intramuscular Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intramuscular Injection
Study: NCT05394506

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Skin Biopsy
Description: The skin biopsy is performed in the consultation outclinic room. A local anaesthetic (anaesthetic patch to be applied to the skin) is required for this procedure. The skin biopsy is usually performed on the front of the forearm (but can be performed on the arm, thigh or leg). After disinfection, a fragment of 3 to 4 mm in diameter is removed with a biopsy-punch (single-use device). If necessary, a suture can be placed. Otherwise, the wound is covered with Steristrip and a sterile dressing. The skin sample, intended for a fibroblast culture, will be placed in a flask to be kept at room temperature. It will be labelled with specific labels and sent to the local biological resource centre.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Muscle biopsy
Description: The muscle biopsy is performed in a sterile room. A local anaesthetic is required for this procedure. After selecting the muscle from which the sample will be taken (usually from the deltoid muscle at the shoulder stump), placing a sterile field and disinfecting, a small incision is made in the skin until the selected muscle is exposed. A bundle of muscle fibres of approximately 1 cm x 0.5 cm is removed. The skin is then sutured and covered with a sterile dressing. The procedure takes about 30 minutes (including patient set-up). The muscle sample will be divided into 2 fragments, one for myoblast culture, the other for frozen tissue. The 2 vials will be labelled with specific labels and then sent to the local biological resource centre
Study: NCT05340673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Agent Affecting Integumentary System
Description: Apply Miaderm

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Petrolatum-Mineral Oil-Lanolin-Ceresin Ointment
Description: Apply to skin

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT06183151

Intervention type: DEVICE
Intervention: Entia Liberty System
Description: See arm/group description
Study: NCT05445141

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Little ACF [in Swedish: Lilla ABC]
Description: Little ACF is a modified version of the program called All Children in Focus \[in Swedish: Alla Barn i Centrum (ABC)\] that originally is developed for parents with children 3-12 years of age. The content is based on positive developmental psychology and involves role plays, discussions and exercises to try at home with the child. Printed material will be provided to the parents at each meeting/session. Little ACF is offered once a week during four weeks. Each session is 60 minutes, thereafter the parents can stay in the facility for 30 minutes to continue discussing with each other.
Study: NCT04766320

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor Infiltrating Lymphocytes (TIL)
Description: Adoptive transfer of 1x10\^9-3x10\^11 autologous TILs to patients i.v. in 30-120 minutes.
Study: NCT05445141

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Lectures
Description: The lectures are pre-recorded and available during four weeks. Each lecture is 10 minutes and the content is similar to, but more superficial than, the content in Little ACF.
Study: NCT03633955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FLT
Description: F18 labeled thymidine PET/CT scans will be performed before and after patient receives therapies.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FLT
Description: F18 labeled thymidine PET/CT scans will be performed before and after patient receives therapies.
Study: NCT05885048

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood samples for analysis
Description: Test hormone levels in blood

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood samples for analysis
Description: Test hormone levels in blood
Study: NCT03633955

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FLT
Description: F18 labeled thymidine PET/CT scans will be performed before and after patient receives therapies.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FLT
Description: F18 labeled thymidine PET/CT scans will be performed before and after patient receives therapies.
Study: NCT05885048

Intervention type: DIAGNOSTIC_TEST
Intervention: Sperm samples for analysis
Description: Spermiogram

Intervention type: OTHER
Intervention: Satisfaction evaluation
Description: Participant satisfaction assessment
Study: NCT04954300

Intervention type: OTHER
Intervention: no intervention
Description: No intervention

Intervention type: OTHER
Intervention: no intervention
Description: No intervention

Intervention type: OTHER
Intervention: no intervention
Description: No intervention
Study: NCT05885048

Intervention type: OTHER
Intervention: Satisfaction evaluation
Description: Participant satisfaction assessment

Intervention type: OTHER
Intervention: Quality of Life questionnaire
Description: The World Health Organization Quality of Life Brief 26-item Version (WHOQOL-BREF)

Intervention type: OTHER
Intervention: Quality of Life questionnaire
Description: The World Health Organization Quality of Life Brief 26-item Version (WHOQOL-BREF)
Study: NCT00758940

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acrysof ReSTOR multifocal IOL
Description: Implanted into the study eye following cataract extraction surgery
Study: NCT03482986

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary habits plan
Description: Patients will be given a personalized plan regarding their diet.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary habits plan
Description: Patients will be given a personalized plan regarding their diet.
Study: NCT05651763

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stimulation and exercise group
Description: Exercise protocol + application of active direct current stimulation for 30 minutes.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Exercise and sham stimulation group
Description: Sham Transcranial direct current stimulation Exercise protocol + application of simulation of direct current stimulation for 30 minutes. The stimulator will be turned off after 30 seconds and the volunteers will not receive current for the rest of the session.
Study: NCT06431191

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lateral raw
Description: lateral raw repair for full tear rotator cuff combined microfracture procedure, without medial raw

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: double raw
Description: double raw repair for full tear rotator cuff combined microfracture procedure
Study: NCT05515406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-7018
Description: ONO-7018 tablet(s) are administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-7018
Description: ONO-7018 tablet(s) are administered orally